Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

Clinical Trial
Study Details
Enrollment
45
Interventions
Description

IV

Name
Cyclophosphamide 50mg
Type
Drug
Description

IV

Name
Abatacept
Type
Drug
Description

IV

Name
Alemtuzumab
Type
Drug
Description

IV

Name
Hydroxyurea
Type
Drug
Description

IV

Name
Thiotepa
Type
Drug
Description

IV

Name
Filgrastim
Type
Drug
Description

IV

Name
Sirolimus
Type
Drug
Description

IV

Name
Azathioprine
Type
Drug
Description

Radiaiton therapy

Name
TBI
Type
Radiation
Description

Hematopoietic Progenitor Cell Infusion

Name
Hematopoietic Progenitor Cell Infusion
Type
Procedure
Phase
Phase 2
Status
RECRUITING
Study ID #
NCT07616154
Study Type
Interventional
Summary

The purpose of this study it to evaluate a reduced toxicity conditioning regimen for haploidentical donor HCT followed by a GVHD prophylaxis regimen comprising of post-transplant cyclophosphamide, sirolimus and abatacept with the goal to improve the GVHD-free rejection-free survival (GRFS) to greater than 90% after haploidentical donor HCT in children and young adults with SCD.

Primary Objective:

\- To assess the GVHD-free and rejection free survival (GRFS) after haploidentical donor HCT in children and young adults with SCD.

Secondary Objectives:

* Assess the overall survival (OS) and disease-free survival (DFS) after haploidentical donor HCT for SCD.
* Estimate incidence and severity of acute and chronic GVHD after haploidentical donor HCT for SCD.
* Assess the neutrophil and platelet engraftment kinetics after haploidentical donor HCT for SCD.

Study Overview
Conditions
Sickle Cell Disease
Contacts and Locations
Locations
Facility

St Jude Children's Research Hospital
Memphis, Tennessee 38105
United States

GeoPoint
35.14953, -90.04898
Status
Recruiting